THE BEST performing stock for 2024 is something of an outlier, Ovoca Bio, with its stock doubling, albeit from a really low 1c price. It is noteworthy that Ovoca fell from a recent high of 13p, which it hit in August last year on the back of Australian trials for its drug, Orenetide, designed to… Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!